



12/07/05 | Press Release

DAVA announces the launch of Oxycodone Hydrochloride Extended-Release 10, 20, 40, and 80 mg Tablets

Fort Lee, New Jersey, December 8, 2005 – DAVA Pharmaceuticals, Inc. (“DAVA”) is proud to announce the introduction of Oxycodone Hydrochloride Extended-Release Tablets (C-II) in 10, 20, 40, and 80 mg dosage strengths. Oxycodone HCL ER is the AB-rated bio-equivalent version of Purdue Pharma L.P.’s OxyContin®. As previously announced on November 7, 2005, DAVA was appointed the exclusive marketer and distributor of Oxycodone HCL Extended-Release tablets C-II, manufactured by IMPAX Laboratories.

DAVA Pharmaceuticals Inc., a specialty pharmaceuticals company, is focused on developing and marketing a broad portfolio of pharmaceutical products. DAVA is aggressively building its product portfolio through a combination of acquisitions, strategic alliances, in-licensing transactions, partnerships and development. DAVA’s headquarters is in Fort Lee, New Jersey. For further information, please visit DAVA’s website located at www.davapharma.com.